GPCRs

G-protein-coupled receptors (GPCRs) are the largest family of human membrane proteins and play a central role in a wide range of biological processes. Despite this, many GPCRs remain therapeutically untapped due to a lack of understanding of their biology and function, as well as difficulties in identifying drug development candidates targeting these highly dynamic proteins.

TECHNOLOGY

Our proprietary technology platform uses conformationally selective V_HH antibodies – ConfoBodies® – to stabilize GPCRs in disease-relevant conformations, facilitating the design of novel medicines with optimal properties. Empowered by our unrivalled Confo® technology and a world-class team of experts in GPCRs, structural biology, computer-aided drug design and medicinal chemistry, we aim to become leaders in the discovery and development of impactful GPCR-modulating medicines.

THERAPEUTICS & COLLABORATION

Our mission is to develop novel GPCR modulators for patients with severe and underserved diseases, with a current emphasis on rare diseases. Beyond developing our own pipeline of small molecules.

ORGANIZATION

As a spin out from the Vrije Universiteit Brussel (VUB) and Vlaams Instituut voor Biotechnologie (VIB) in 2015, we operate across two sites in Belgium, one in Ghent and the other in Brussels.

Led by an experienced and dynamic leadership team, we have raised over €40 million and are supported by a strong syndicate of international investors.

Confo Therapeutics products

Pipeline

Confo - Pre Clinical Drug Discovery